Biogen's Litifilimab Shows Durable Lupus Skin Relief at 52 Weeks
New Phase 2 data from Biogen's AMETHYST study show litifilimab sustains skin disease improvements through one year in cutaneous lupus patients.
Biogen Inc. reported 52-week data Thursday from the Phase 2 portion of its ongoing AMETHYST Phase 2/3 trial evaluating litifilimab in patients with cutaneous lupus erythematosus, a chronic autoimmune condition that causes inflammatory skin lesions. The findings, presented at the European Academy of Dermatology and Venereology Congress in Vienna, represent the longest dataset yet published for the experimental drug in this indication.
Patients who received litifilimab throughout the double-blind, placebo-controlled period continued to show measurable reductions in skin disease activity through Week 52, suggesting the treatment effect is not only sustained but potentially deepening over time. The company characterized the results as reinforcing litifilimab's profile as a potential first-in-class therapy for the condition, for which treatment options remain limited.
Read more Adapt Relaunches Late Pay Agent for Automated Payment Collection →
A notable secondary finding emerged from participants who crossed over from placebo to active treatment at the 24-week mark. Those patients began showing clinical response as early as four weeks after the switch, pointing to a relatively rapid onset of effect that could be meaningful to both clinicians and patients managing a disease with significant quality-of-life burden.
The AMETHYST trial is ongoing, with Phase 3 data still to come. Analysts will be watching whether the durability and speed of response seen in the smaller Phase 2 cohort hold up at larger scale, a threshold that would be critical for any future regulatory submission. Biogen trades on the Nasdaq under the ticker BIIB.
Continue reading at GlobeNewswire - Industry News on Financial Services.
